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Background: Single Base Substitutions (SBS) that alter transcripts expressed in cancer originate from somatic
mutations. However, recent studies report SBS in transcripts that are not supported by the genomic DNA of tumor
cells.
Methods: We used sequence based whole genome expression profiling, namely Long-SAGE (L-SAGE) and Tag-seq
(a combination of L-SAGE and deep sequencing), and computational methods to identify transcripts with greater
SBS frequencies in cancer. Millions of tags produced by 40 healthy and 47 cancer L-SAGE experiments were
compared to 1,959 Reference Tags (RT), i.e. tags matching the human genome exactly once. Similarly, tens of
millions of tags produced by 7 healthy and 8 cancer Tag-seq experiments were compared to 8,572 RT. For each
transcript, SBS frequencies in healthy and cancer cells were statistically tested for equality.
Results: In the L-SAGE and Tag-seq experiments, 372 and 4,289 transcripts respectively, showed greater SBS
frequencies in cancer. Increased SBS frequencies could not be attributed to known Single Nucleotide
Polymorphisms (SNP), catalogued somatic mutations or RNA-editing enzymes. Hypothesizing that Single Tags (ST), i.
e. tags sequenced only once, were indicators of SBS, we observed that ST proportions were heterogeneously
distributed across Embryonic Stem Cells (ESC), healthy differentiated and cancer cells. ESC had the lowest ST
proportions, whereas cancer cells had the greatest. Finally, in a series of experiments carried out on a single patient
at 1 healthy and 3 consecutive tumor stages, we could show that SBS frequencies increased during cancer
progression.
Conclusion: If the mechanisms generating the base substitutions could be known, increased SBS frequency in
transcripts would be a new useful biomarker of cancer. With the reduction of sequencing cost, sequence based
whole genome expression profiling could be used to characterize increased SBS frequency in patient’s tumor and
aid diagnostic.
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In mammalian cells, genetic integrity is maintained by
stability genes [1] which are in charge of correct
chromosomal segregation and recombination; damaged
DNA repair; accurate genomic DNA replication and
transcriptional fidelity. In healthy cells, base substitu-
tions occur at an extremely low incidence during both
DNA replication [2] and RNA synthesis [3]. Single base
variations can be the result of Single Nucleotide Poly-
morphisms (SNP) [4] or RNA-editing carried out by
ADAR [5] or APOBEC [6] enzymes. By contrast, genetic
instability is a hallmark of cancer [7,8]. Major mutational
events such as chromosome region translocations, dele-
tions and gene copy number variations have been
reported in almost all cancer cells [9]. Somatic muta-
tions, i.e. acquired or inherited SBS which differentially
alter cancer cell genomes and consequently transcript
sequences, were reported on a genome wide scale using
deep sequencing [10,11]. Now, a census of cancer related
somatic mutations that alter 422 human genes has been
made available [12]. A growing body of cancer studies
reports SBS in transcripts that are not supported by the
genome of tumor cells. Using EST alignments on refer-
ence mRNA sequences, Brulliard M. et al. proved that
15 abundantly expressed transcripts, namely GAPDH,
VIM, FTH1, ENO1, HSPA8, TPT1, RPS4X, ATP5A1,
FTL, RPL7A, TPI1, RPS6, ALDOA, LDHA and CALM2
had statistically greater SBS frequencies in cancer than
in healthy cells whereas ALB and TSMB4X showed the
opposite [13]. Since most EST are 3’ fragments of mRNA
sequences, increased SBS in cancer was detected at the
3’ boundary of mRNA. These SBS could not be
explained by known SNP and were also unlikely the re-
sult of somatic mutations or RNA-editing enzymes. The
possibility that instruments generated more sequencing
errors when EST originated from cancer cells does not
seem rational. As a working hypothesis, the concept of
transcriptional infidelity (TI) was proposed: i) TI intro-
duces non-random base variations in RNA sequences
that are not supported by the genome ii) TI exists in
both healthy and cancer cells, but is greater in cancer.
Increased TI in cancer has been speculated to originate
from a defective proofreading activity of RNA poly-
merases. Recently, in a study carried out at both gen-
omic and transcriptional levels, SRP9 and COG3 mRNA
expressed in tumor cells were clearly shown to carry
SBS that were conflicting with the genome sequence
[14]. SRP9 sequencing chromatogram traces showed an
adenine (in tumor DNA) and a guanine (in tumor RNA)
substitution which might be attributed to ADAR, in fact
ADAR carries out adenosine to inosine editions and in-
osine is read as guanosine by sequencing instruments.
Intriguingly, in the case of COG3, a thymine (in tumor
DNA) was replaced by a cytidine (in tumor RNA) whichcannot be carried out by ADAR nor APOBEC enzymes
because APOBEC converts cytosine to uracile in RNA
sequences. Personalized omics profiling also concurred
on the fact that RNA-editing is extensively carried out in
peripheral blood mononuclear cells with more than
2300 target sites and approximately 50% of them were
not typical ADAR or APOBEC edits [15]. Deregulation
of RNA-editing, e.g. adenosine to inosine hypoediting,
was also reported in tumors [16]. To identify mRNA
with greater SBS frequencies in cancer, we performed a
bioinformatics analysis of 7.6 million tags produced by
87 human L-SAGE [17] experiments (a molecular biol-
ogy method using Sanger sequencing), and 67.8 million
tags generated by 15 human Tag-seq experiments (a
combination of L-SAGE and deep sequencing) [18,19].
Both L-SAGE and Tag-seq generate short sequences that
are likely localized on the 3’ boundary of transcripts.
Therefore, L-SAGE and Tag-seq may prove useful to de-
tect SBS introduced in the 3’ boundary of transcripts.
Briefly, tags are short sequences of 17 bases which are
signatures of 3' polyadenylated transcripts expressed in
cells. The most 3’ NlaIII “CATG” motif in the transcript
sequence is directly followed by the 17 base tag. More-
over, tag counts and mRNA expression levels are corre-
lated. Comparing tags to RT sequences, i.e. tags
matching the human genome exactly once, we showed
that a plethora of transcripts had greater SBS frequen-
cies in cancer cells. Although the genomic sequences of
the tumor and the healthy cells were not simultaneously
available in our study, these SBS could not be attributed
to known SNP, catalogued cancer related somatic muta-
tions, and known APOBEC1 or ADAR editing. ST pro-
portions, i.e. proportions of tags sequenced only once
were calculated for each experiment and were used as
an indicator of SBS frequency. Interestingly, among
healthy cells, ESC had the lowest ST proportions which
might indicate that transcriptional fidelity could be
increased in ESC. Conversely, the greatest ST propor-
tions were observed in cancer cells. Finally, focusing on
a series of 4 L-SAGE experiments carried out on the
biopsies of a single patient at 1 healthy and 3 conse-
cutive tumor stages, we were able to demonstrate that
SBS frequencies significantly increased during cancer
progression.
Methods
L-SAGE and Tag-seq experiments
The GPL1485 platform of the NCBI Gene Expression
Omnibus (GEO) server is a repository of L-SAGE and
Tag-seq experiments carried out on human cells. In the
GPL1485, the GSE1902 (L-SAGE) and GSE15314 (Tag-
seq) series of experiments were selected. All experiments
were carried out using the NlaIII anchoring enzyme
which cuts 3’ polyadenylated transcripts at CATG sites.
Bianchetti et al. BMC Cancer 2012, 12:509 Page 3 of 13
http://www.biomedcentral.com/1471-2407/12/509Experiments were separated into 2 groups, namely
healthy and cancer using a dictionary of cancer related
terms: adenocarcinoma, cancer, carcinoma, dysplasia,
fibroadenoma, glioblastoma, leukemia, lymphoma, me-
dulloblastoma, melanoma, tumor, retinoblastoma and
rhabdomyosarcoma. The Sybase system was used to store
the tags of L-SAGE and Tag-seq experiments. Programs
were run on a 6 × 4 Sun AMD Opteron processors
(2.6 GHz) under the linux operating system.
Reference tags (RT)
RT were selected among the tags produced by the
L-SAGE and Tag-seq experiments. Tags should fulfill 2
criteria to be selected i) presence in at least 75% of
L-SAGE or 90% of Tag-seq experiments ii) exactly one
match on the human genome sequence. Tags that ful-
filled the first criteria were selected using a JAVA pro-
gram and were subsequently aligned on the human
genome using a blastn tool. Two distinct lists of RT
were thus created, 1 for the L-SAGE and 1 for the Tag-
seq experiments.
Single base substituted RT (sbsRT)
For each RT, and for each of the 17 base positions, a nu-
cleotide was replaced by a "_" metacharacter. Thus, 17
distinct patterns were generated (Additional file 1). A Java
program was written to automatically i) generate the 17
distinct patterns ii) retrieve from the database of L-SAGE
and Tag-seq experiments all the tags that matched the
patterns and iii) sum the tag counts. The risk that a sbsRT
could match by chance a RT was calculated (Additional
file 2) and equaled 6.5 × 10-5. Thus, any tag that was iden-
tical to a RT except at 1 base position, was very likely the
result of a SBS that had occurred in this RT.
Testing for SBS frequency equality in transcripts
expressed in healthy and cancer cells
Let C and H be the number of cancer and healthy
L-SAGE experiments (or Tag-seq experiments). For each
RT, 4 sum of counts (Sc) were calculated (i, ii, iii and iv):
i. Sum of counts of the RT across all healthy
experiments Sc _ H _ RT =
P
k = 1
H RT count in exp. k
ii. Sum of counts of the RT across all cancer
experiments Sc _ C _ RT =
P
k = 1
C RT count in exp. k
iii. Sum of counts of sbsRT (associated with the RT)
across all healthy experiments Sc _ H _ sbsRT =P
k = 1
H P
i = 1
51 sbsRTi count
iv. Sum of counts of sbsRT (associated with the RT)
across all cancer experiments Sc _ H _ sbsRT =P
k = 1
H P
i = 1
51 sbsRTicount
Then, for each RT, 2 sbsRT proportions were calcu-
lated (i, ii):i) sbsRT proportion across all healthy experiments
sbsRT prop H ¼ Sc H sbsRTSc H RTþSc H sbsRT
ii) sbsRT proportion across all cancer experiments
sbsRT prop C ¼ Sc C sbsRTSc C RTþSc C sbsRT
Finally, for each RT, two 1-side Pearson’s chi-squared
proportion tests (i, ii) were carried out using a 0.025 α
type I error
i) Pearson’s chi-squared proportion test (Cancer >
Healthy):
H0 : "sbsRT_prop_C equals sbsRT_prop_H"
H1: "sbsRT_prop_C is greater than sbsRT_prop_H"
ii) Pearson’s chi-squared proportion test (Healthy >
Cancer)
H0 : "sbsRT_prop_C equals sbsRT prop_H"
H1: "sbsRT_prop_H is greater than sbsRT_prop_C"
A script was written in the R environment to carry out
the Pearson’s chi-squared proportion tests. For a RT, and
thus a transcript, the Ho hypothesis was rejected when a
p-value less than 0.025 was obtained. Three lists of RT
were thus produced according to the decision of the
Pearson’s chi-squared proportion test i) RT for which
proportions of sbsRT were greater in cancer than in
healthy, ii) RT for which proportions of sbsRT were
greater in healthy than in cancer iii) RT for which pro-
portions of sbsRT in cancer and healthy were not signifi-
cantly different.
Global proportions of sbsRT
Global proportions were calculated for selected experi-
ments. Across a set of experiments (e. g. same healthy
tissue), RT that were present in 100% of the experiments
were selected. Let N be the number of RT that were
present in all experiments. The sum of RT counts and
the sum of their associated sbsRT counts were calcu-
lated. Finally a global proportion of sbsRT across the set
of experiments was computed as follows:
global sbsRT proportion
¼
XN
1
sbsRT counts
XN
1
RT counts þ
XN
1
sbsRT counts
Global sbsRT proportions were tested for equality
across different healthy tissues using the Analysis of
Variance (Anova).
Single tags (ST)
ST are tags that were sequenced only 1 in a L-SAGE ex-
periment, i.e. ST were associated with a count of 1. For
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defined and the proportion of ST on total tags could be
calculated. ST was not reported in Tag-seq experiments.
In fact, counts were greater than 1 which showed that
ST had been discarded from Tag-seq experiments.
ST proportions
For each L-SAGE experiment, the proportion of ST was
calculated:
ST proportion ¼ n
total tags
where n is the number of ST and total_tags is the sum
of counts.
Known SNP that altered 17 base NlaIII tags of transcripts
A file of 17 base NlaIII tags associated with known SNP
was provided by Dr. Anamaria Camargo. In this file,
each line recorded a Genbank mRNA accession number,
the NlaIII 17 base tag associated with the mRNA and
the sequence of the tag with the known SNP. The file
contained 4,697 entries. It was thus possible to identify
sbsRT that were the result of known SNP.
Census of genes with cancer related somatic mutations
A census of somatically mutated genes in cancer was
downloaded from the COSMIC database (v56). Known
somatic mutations were recorded for 422 distinct genes
which were identified by NCBI Gene ID. In our study,
transcripts were identified with Genbank or RefSeq ID
and thus were converted to NCBI gene ID using the
Synergizer tool [20]. Area proportional Venn diagrams
were drawn to determine whether known somatically
mutated genes were present among the genes with
greater SBS frequencies. Bases that were somatically
mutated in cancer and recorded by COSMIC were loca-
lized on transcript sequences and their proximity or in-
clusion to the 17 base NlaIII tag was determined.
Validated and predicted APOBEC1 and ADAR RNA-editing
targets
APOBEC1 RNA-editing targets. A series of 32 editing sites
in 30 distinct transcripts are known substrates for the
Apoliprotein B-editing enzyme, catalytic polypeptide-1
(APOBEC1) in mouse. Using an APOBEC1 specific edit-
ing sequence pattern, namely WCWN2-4WRAUYANUAU
(mooring sequence), which is located directly 3’ to the edi-
ted cytosine, Rosenberg B. R. et al. predicted 376 editing
sites in 363 distinct mouse transcripts. Out of these 363
transcripts, ten were previously experimentally validated,
in particular, the prototypic ApoB editing site. Thus 383
distinct mouse transcripts either predicted or validated
APOBEC1 RNA-editing targets are available. However,our study was carried out on human sequences. There-
fore, conservation of RNA-editing targets between human
and mouse organisms was hypothesized. Human ortholo-
gues of mouse RNA-editing targets were retrieved from
RefSeq by sequence similarity searches using blastn. Top
scoring human transcripts were assumed to be ortholo-
gues of mouse transcripts targeted by the APOBEC1.
RefSeq ID were then converted to NCBI gene ID with the
Synergizer tool. A list of 361 unique NCBI gene ID was
thus produced for the human transcripts. Venn diagrams
were drawn to identify human transcripts which could be
APOBEC1 RNA-editing targets and showing greater SBS
frequencies in cancer or healthy cells. These transcripts
were compared with the mouse orthologues to determine
the local level of similarity between mouse and human
mooring sequences. Pairwise sequence comparison was
carried out using the Smith and Waterman local algo-
rithm implemented in the water program of the EMBOSS
package (gap opening penalty 10, gap extension penalty
0.5, EDNAFULL matrix). When the mooring sequences
were conserved between mouse and human, the 17 base
NlaIII tag was localized on the human transcript. Finally,
proximity between the 17 base NlaIII tag and the mooring
sequence was determined and the possibility that the 17
base NlaIII tag could be edited by the APOBEC1 enzyme
was assessed.
ADAR RNA-editing targets. Most A-to-I susbstitu-
tions occur within interspersed repetitive elements
mainly in Alu sequences. Since RT match the human
genome exactly once, they are very unlikely located in
Alu repeats. Therefore, sbsRT may not be the result of
ADAR RNA-editing.
Results
Groups of healthy and cancer experiments
87 L-SAGE and 15 Tag-seq experiments were selected
on the NCBI Gene Expression Omnibus (GEO) reposi-
tory [21]. L-SAGE experiments were grouped into 40
healthy and 47 cancers. Sixteen different tissues or cell
types were represented (Additional file 3). Tag-seq
experiments were grouped into 7 healthy and 8 cancers.
All selected Tag-seq experiments originated from skin
or foreskin biopsies. Since the total number of tags pro-
duced by L-SAGE and Tag-seq experiments were dra-
matically different and because the sequencing error
rates of Sanger and deep sequencing methods may be
unequal, L-SAGE and Tag-seq tags were processed
using the same bioinformatics workflow but separately
(Figure 1).
Reference Tags (RT)
2,930 tags were present in at least 75% of the 40
healthy and at least 75% of the 47 cancer L-SAGE
experiments. Among these 2,930 tags, 1,966 matched
tags with unique match 
on the human genome 
87 L-SAGE  and  15 Tag-seq experiments 
healthy
tags present in most 
healthy and cancer 
experiments 
4)
cancer
1)
2)
RT
3)
sbsRT 
RT+sbsRT 
in healthy 
sbsRT 
RT+sbsRT 
in cancer 
7)
5)
6)
tag with 
known SNP 
8) =
prop. test 
Collect of sbsRT in both healthy and cancer
Ho
Figure 1 Bioinformatics workflow. 1) L-SAGE and Tag-seq experiments were processed separately 2) Experiments were divided in 2 groups,
namely healthy and cancer 3) tags (thin black arrow) present in at least k% of healthy and at least k% of cancer experiments (k = 75% for L-SAGE
and k = 90% for Tag-seq) were selected 4) The tags 5' boundaries were extended with the CATG (NlaIII) motif generating 4 + 17 = 21 base
sequences and aligned on the human genome (long and thick black line) using blastn 5) tags matching the human genome exactly once were
selected as RT (thick black arrow) 6) For each RT, sbsRT (thick black arrows carrying an ellipse) were searched among all the tags and were
collected with their counts. 7) sbsRT matching a known SNP were excluded from SBS accounting (discontinuous rectangle) 8) For each RT, i.e. for
each transcript, 2 proportions of sbsRT were calculated, i.e. 1 in healthy and 1 in cancer. Finally, both proportions were statistically tested for
equality.
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had a sequence composition bias and were discarded.
Thus, 1,959 distinct tags were selected as RT (= L-
SAGE list of RT). 11,967 tags were present in at least
90% of the 7 healthy and at least 90% of the 8 cancer
Tag-seq experiments. Among these 11,967 tags, 8,806
matched the human genome sequence exactly once,
234 were discarded because of sequence composition
bias and 8,572 distinct tags were selected as RT
(=Tag-seq list of RT). 1,878 tags were common to
both L-SAGE and Tag-seq lists of RT. In theory, a
RT can generate 51 (= 3 × 17) possible distinct
sequences by SBS, therefore each RT may be asso-
ciated with 51 sbsRT. For each RT, the frequencies of
sbsRT in both cancer and healthy cells were calcu-
lated. COG3 (alias SEC34) and SRP9 3’ polyadeny-
lated transcripts were recorded in genbank with
AF332595 and EF488978 accession numbers respect-
ively. The 17 base NlaIII tags of SRP9 and COG3
transcripts were determined using genbank sequence
records. However, SRP9 and COG3 17 base NlaIII
tags were not present among the L-SAGE and Tag-
seq lists of RT. Conversely, GAPDH, VIM, ENO1,
HSPA8, TPT1, ATP5A1, FTL, TPI1, ALDOA andLDHA 17 base NlaIII tags were present among the L-
SAGE or Tag-seq lists of RT.
Increased SBS frequencies in transcripts expressed in
cancer cells
For each of the 1,959 RT that were selected using L-
SAGE experiments, sbsRT proportions in cancer and
healthy cells were tested for equality (Ho) against the al-
ternative hypothesis that sbsRT proportions were greater
in cancer cells (H1): Ho was rejected for 529 out of 1,959
RT by multiple 1-side Pearson’s chi-squared proportion
tests with α/2 = 0.025 risk of type I error. A Benjamini-
Hochberg False Discovery Rate (FDR) was applied and
372 out of 529 RT passed FDR at 2.5%. As a result, 372
RT (19% of 1,959) showed significantly greater SBS in
cancer than in healthy cells (Additional file 4). The same
Ho was tested against the alternative hypothesis that
sbsRT proportions were greater in healthy cells (H1): Ho
was rejected for 66 RT by multiple 1-side Pearson’s chi-
squared proportion tests with α/2 = 0.025 and 17 RT
passed FDR at 2.5%, i.e. ~0.9% of 1,959. No difference
between cancer and healthy cells was detected for 1,570
RT (80%). RT were associated with transcripts using the
Sagettarius tool [22]. Among the RT with top ranking
Table 1 Testing SBS frequency equality in healthy (H) and
cancer (C) cells for the 17 mRNA selected by Brulliard, M.
et al. (2007)
Gene COSMIC L-SAGE Tag-seq Brulliard, M.
et al. TI
study using
EST
GAPDH 0 C > H (3.67×10-115) C > H (~0) C > H
VIM 13 C = H C > H (2.32×10-78) C > H
ENO1 7 C > H (3.48×10-3) C < H (0.76×10-2) C > H
HSPA8 10 RT C > H (9×10-9) C > H
TPT1 0 C > H (4.05×10-4) C > H (~0) C > H
ATP5A1 5 C > H (1.51×10-15) C > H (1.35x10-83) C > H
FTL 0 RT C > H (1.5×10 -7) C > H
TPI1 3 C > H (1.14×10-52) C > H (~0) C > H
ALDOA 4 C = H C < H (5.55×10-23) C > H
LDHA 4 C > H (6.98×10-14) C > H (1.84×10-3) C > H
FTH1 5 RT RT C > H
RPS4X 2 RT RT C > H
RPL7A 1 3’ polyadenylated RNA
record not available
C > H
RPS6 0 RT RT C > H
CALM2 1 RT RT C > H
TMSB4X 1 RT RT C < H
ALB 17 RT RT C < H
C > H: greater SBS frequency in cancer. C < H: greater SBS frequency in healthy.
C = N: SBS frequencies are not significantly different between H and C. RT: the
17 base NlaIII tag associated with this transcript was not present in either L-
SAGE or Tag-seq lists of RT and therefore equality between SBS frequencies in
H and C could not be tested. COSMIC: number of cancer related somatic
mutations recorded by the COSMIC database. 3’ polyadenylated RNA record
not available: the sequence recorded in RefSeq-rna does not have a 3’
polyadenylated boundary, therefore NlaIII tag cannot be determined.
Figure 2 Venn diagrams of transcripts with greater SBS frequencies a
gene ID. Venn diagram areas are proportional to gene ID numbers. (a) Left
cancer, right circle = transcripts with greater SBS frequencies in cancer than
to both lists. For each of these 9 transcripts, no known cancer-related soma
(v56) census of 422 somatically mutated genes in cancer. Left circle = trans
Tag-seq experiments. Sixty eight transcripts were common to both lists. Fo
mutations altered the 17 base NlaIII tag.
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present, i.e. 2 mRNA that had been previously reported
by Brulliard M. et al. using EST aligned on reference
transcripts. Interestingly, no somatic mutation was
recorded in the COSMIC database [23] for both genes,
indicating that SBS observed at the transcript level were
not supported by any known base variation at the gen-
ome level. Since known SNP occurring in NlaIII tags
[24] were excluded from sbsRT accounting, SNP could
not support the increased SBS frequency in cancer. Fur-
ther transcripts identified by the EST study, namely
ATP5A1, TPT1, LDHA and ENO1 were also present
among the 372 RT. In conclusion, 6 mRNA out of the
15 identified by Brulliard M. et al. were confirmed
(Table 1). SBS frequencies were calculated for each of
the 8,572 RT selected using the Tag-seq experiments.
SBS frequencies in healthy and cancer cells were tested
for equality (Ho) against the alternative hypothesis that
sbsRT proportions were greater in cancer (H1): Ho was
rejected by multiple 1-side Pearson’s chi-squared propor-
tion tests with a α/2 = 0.025 for 4,465 RT. 4,289 RT
passed FDR at 2.5%. As a result, 4,289 RT (50% of 8,572)
showed significantly greater SBS in cancer than in
healthy cells (Additional file 5). The same Ho was tested
against the alternative hypothesis that sbsRT proportions
were greater in healthy cells (H1): Ho was rejected for
1,417 RT by multiple 1-side Pearson’s chi-squared pro-
portion tests with a α/2 = 0.025, 1,123 RT passed FDR at
2.5% (13%). For 3,160 RT (37%), no difference was
observed between healthy and cancer cells. Using Tag-
seq experiments, the list of RT showing greater SBS fre-
quencies in cancer was 11.5 times longer than the list
produced by L-SAGE experiments. Thus, both L-SAGE
and Tag-seq experiments concurred with the notion thatnd genes with cancer somatic mutations. Numbers represent NCBI
circle = COSMIC (v56) census of 422 somatically mutated genes in
in healthy cells in L-SAGE experiments. Nine transcripts were common
tic mutations altered the 17 base NlaIII tag. (b) Right circle = COSMIC
cripts with greater SBS frequencies in cancer than in healthy cells in
r each of these 68 transcripts, no known cancer related somatic
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in healthy cells. Nine out of the 15 transcripts identified
by the EST study were confirmed by the Tag-seq experi-
ments (Table 1).
Known cancer somatic mutations do not support
increased SBS frequencies in mRNA
A census of 422 genes that are somatically mutated in
cancer has been made available by the COSMIC data-
base. Venn diagrams were drawn between the census of
somatically mutated genes and the transcripts that had
greater SBS in cancer than in healthy cells using
L-SAGE (Figure 2a) and Tag-seq (Figure 2b) experi-
ments. Nine genes were common to the census and
L-SAGE transcripts and 68 were common to the census
and the Tag-seq transcripts. We thoroughly checked
whether known somatic mutations altered the 17 base
NlaIII tag for each of the 9 (Additional file 6) and 68
(Additional file 7) genes. The 17 base NlaIII tag was gen-
erally located in the vicinity of the transcript 3’ polyade-
nylated boundary, i.e. in the 3’ UTR. For a majority ofFigure 3 Venn diagrams of transcripts with greater SBS frequencies a
Venn diagram areas are proportional to gene ID numbers. (a) Left circle = A
SBS frequencies in cancer cells in L-SAGE experiments. (b) Left circle = APO
SBS frequencies in healthy cells in L-SAGE experiments. (c) Right circle = AP
frequencies in cancer cells in Tag-seq experiments. (d) Right circle = APOBE
frequencies in healthy cells in Tag-seq experiments.genes, the most 3’ known somatic mutation altered the
coding sequence of the gene and was thus 5’ to the 17
base NlaIII tag. No known somatic mutation altered the
17 base NlaIII tags. Therefore, the increased SBS fre-
quencies that were observed in transcripts expressed in
cancer cells could not be attributed to known somatic
mutations.
APOBEC1 or ADAR RNA-editing do not support increased
SBS frequencies
Rosenberg B.R. et al. published a list of 32 experimen-
tally validated APOBEC1 mRNA-editing sites in 30 dis-
tinct mouse transcripts. Comparing the transcript
sequences surrounding the C to U edition position, a
mooring pattern, i.e. WCWN2-4WRAUYANUAU, had
been defined. Moreover, the RNA-editing site occurs in
a 16 base region directly 5’ to the mooring sequence.
Rosenberg B.R. et al. used the mooring pattern to predict
additional transcripts that could be edited by APOBEC1.
Finally, a list of 383 transcripts (=361 NCBI gene ID
after synergizer conversion) was proposed as eithernd APOBEC1 RNA-editing targets. Numbers represent NCBI gene ID.
POBEC1 RNA-editing targets, right circle = transcripts with greater
BEC1 RNA-editing targets, right circle = transcripts with greater
OBEC1 RNA-editing targets, left circle = transcripts with greater SBS
C1 RNA-editing targets, left circle = transcripts with greater SBS
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Figure 4 Diversity of sbsRT in healthy and cancer cells. SBS
were tracked for 8,572 RT in 7 healthy (circles) and 8 cancer
(triangles) Tag-seq experiments. The 8,572 RT were distributed into
sequence diversity groups according to the number of distinct
sbsRT sequences. For example, group 0, i.e. RT for which 0 sbsRT
were observed, contained approximately 350 RT in cancer and
slightly more than 800 RT in healthy cells. RT associated with more
than 30 distinct sbsRT were rare.
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BEC1. We crossed this APOBEC1 list of RNA-editing
targets with the 372 transcripts (=301 NCBI gene ID
after synergizer conversion) that showed greater SBS fre-
quencies in cancer than in healthy cells using L-SAGE
experiments. Five transcripts were common to both lists
(Figure 3a). For each of the 5 transcripts, the positions
of the 17 base NlaIII tag and the mooring sequence were
determined. None of the 17 base NlaIII tags could be
potentially edited by APOBEC1 because the mooring se-
quence and the tag were distant from each other in the
transcript sequence (Additional file 8). The beta-2
microglobulin was the only transcript common to both
APOBEC1 RNA-editing targets and transcripts with
greater SBS in healthy than cancer cells (Figure 3b).
However, the mooring sequence was not conserved be-
tween mouse and human beta-2 microglobulin tran-
scripts. Using Tag-seq, 53 transcripts that had greater
SBS in cancer were present among APOBEC1 RNA-
editing targets (Figure 3c), and 8 of them had been
experimentally validated. However, none of these 8 tran-
scripts had a 17 base NlaIII tag that overlapped the
APOBEC1 editing site (Additional file 9). Finally, for
transcripts with greater SBS in healthy than cancer
obtained using Tag-seq, only 1, namely FARSB, had a 17
base NlaIII tag that overlapped the APOBEC-1 RNA-
editing site. We thus cannot exclude that increased SBS
frequency observed for FARSB could be the result of an
APOBEC1 edition. Adenosine to inosine conversions
carried out by the ADAR family of RNA-editing enzymes
occur in non-coding repetitive sequences, mostly Alu
elements. Alu sequences are dispersed along the genome
and can also be integrated in mRNA. Since RT mono-
localize on the genome, they cannot match Alu
sequences, which excludes that increased SBS frequen-
cies that were observed in transcripts expressed in can-
cer or healthy could originate from ADAR editions.
Wide range of molecular functions potentially affected by
increased SBS frequencies
For L-SAGE, 1,879 (96%) RT out of 1,959 could be asso-
ciated with a transcript (=L-SAGE background list). 355
RT out of the 372 that showed greater SBS frequencies
in cancer (=L-SAGE query list) associated with a
transcript. GO analysis using DAVID [25] determined
that the “Translation” biological process was over-
represented among the 355 transcripts (p-value = 6×10-7,
Benjamini-Hochberg = 10-3). The “Ribosome” cellular
localization was also enriched (p-value = 1.8×10-5,
Benjamini-Hochberg = 5.7×10-3). For Tag-seq experi-
ments, 7,830 (91%) RT out of 8,572 were mapped to a
transcript (=Tag-seq background list). Among the 4,289
RT that showed greater SBS in cancer, 3,953 could be
associated with a transcript (=Tag-seq query list n°1).1,053 (94%) out of the 1,123 RT that showed greater
SBS in healthy cells associated with a transcript (=Tag-seq
query list n°2). However, no GO term enrichment was
present in both Tag-seq query lists. As a result, many dif-
ferent biological processes or molecular functions could
be potentially represented among transcripts with greater
SBS in cancer.
Increased diversity of SBS in transcripts expressed in
cancer cells
The diversity of sbsRT sequences was not studied using
L-SAGE experiments because the sums of total tags in
healthy (4.7 million) and cancer (2.9 million) were unba-
lanced. By contrast, in the Tag-seq experiments, the sums
of total tags counts in healthy and cancer cells were quite
balanced, i.e. 33.4 and 34.4 million (+3%), respectively.
For each of the 8,572 RT, the number of distinct sbsRT
sequences i) in healthy and ii) in cancer was determined.
In healthy and cancer, the 8,572 RT generated 60,854 and
76,967 (+26%) distinct sbsRT sequences, respectively.
Thus, sbsRT diversity was greater in cancer and this
could not be explained by the +3% difference in the sums
of total tags counts. The 8,572 RT were separated into
groups according to the number of distinct sbsRT
observed in cancer or healthy cells, i.e. the ith group con-
tained the RT for which exactly i distinct sbsRT were
observed. All RT associated with 0 to 44 distinct sbsRT
sequences. Maximal diversity of 51 distinct sbsRT was
never observed for any RT. In experiments carried out in
healthy and cancer cells, 825 and 356 RT were associated
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Figure 5 ST proportions calculated for each L-SAGE
experiment. Each symbol represents 1 experiment: 47 cancer
(triangles) and 40 healthy (circles), circles filled with gray = ESC,
triangles filled with black = L-SAGE experiments carried out on the
tumor cells of a single patient, circle filled with black = L-SAGE
experiment carried out on the healthy cells of the same patient.
Experiments were sorted in ascending ST proportion order.
Figure 6 Distribution of ST proportions and global sbsRT proportions
namely "Breast" (12 experiments), "ESC" (10 experiments) and "White Blood
proportion and the (b) global sbsRT proportion were calculated. 583 RT we
global sbsRT proportion, respectively.
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had 8 or less distinct sbsRT sequences in healthy and
cancer, respectively. Conversely, 3,291 and 4,524 RT had
more than 8 sbsRT in healthy and cancer respectively.
RT seemed thus heterogeneously distributed between
cancer and healthy cells when analyzing sbsRT diversity
(χ2 test at α = 5%, p-value < 2.2 x 10-16). We concluded
that i) cancer introduced heterogeneity in sbsRT diversity
ii) sbsRT diversity was greater in cancer.Heterogeneity of ST proportions across healthy and
cancer cells
ST were not reported in Tag-seq experiments on GEO
records. In fact, tags counts were greater or equal than
2. Conversely, ST were reported in L-SAGE. First, ST
proportions were calculated for each of the 87 L-SAGE
experiments. Second, these proportions were sorted in
ascending order (Figure 5). Most experiments had ST
proportions in the range of 0.25 to 0.42. However, a
group of 10 experiments carried out in healthy cells,
namely ESC, showed ST proportions that were lower
than any other (~0.2). Furthermore, the greatest ST pro-
portions were observed in cancer cells. Interestingly,
within a series of 4 L-SAGE experiments carried out on
the biopsies of a single patient at 1 healthy and 3 disease
stages, the ST proportions were greater in cancer cells
than in healthy cells.in 3 distinct healthy tissues. 32 L-SAGE experiments were used,
Cells" (WBC) (10 experiments). For each experiment, the (a) ST
re used for Breast, 1.478 for ESC, and 860 for WBC to calculate the
00.1
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Figure 7 Single patient personalized monitoring of ST and
global sbsRT proportions during disease progression. ST and
global sbsRT proportions were calculated for 4 L-SAGE experiments
carried out on the biopsies of a single patient at 1 healthy and 3
consecutive tumor stages. Gray bars = ST proportions, black bars =
global sbsRT proportions. Low-grade dysplasia (LGD), High-grade
dysplasia (HGD) and adenocarcinoma (cancer). The global sbsRT
proportions were calculated using 1.435 RT present in all 4
experiments. Significance of ST proportion differences between
healthy, LGD, HGD and adenocarcinoma was calculated using the
Pearson’s chi-squared proportion test (p-value < 2.2 x 10-16).
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Remarkably, ESC had ST proportions ranging between
0.15 and 0.23. To test the significance of this difference,
experiments carried out in most represented healthy tissues
were separated into 3 groups, namely breast (12 experi-
ments), White Blood Cells (WBC) (10 experiments) and
ESC (10 experiments). For breast, WBC and ESC, the me-
dian of ST proportions were 0.33, 0.31 and 0.19, respect-
ively (Figure 6a). A one way-Analysis of variance (Anova)
with the "cell type" factor at 3 modalities (breast, WBC,
ESC,) was carried out. A mathematical transformation was
applied to the proportions, i.e. the arcsin(square root(ST
proportion)). The transformed proportions were considered
independent since the experiments were carried out on dif-
ferent cell types (Anova 1st condition). A Shapiro-Wilk test
was applied to check the distribution normality of the
transformed proportions for each of the 3 cell types (breast:
p-value = 0.8978; WBC: p-value = 0.6676; ESC: p-value =
0.9206), the hypothesis of "normal distribution" were thus
accepted (Anova 2nd condition). The hypothesis of variance
equality between breast, ESC and WBC was accepted using
the Bartlett test (Anova 3rd condition) (p-value = 0.88). Fi-
nally, the equality of ST transformed proportion means
across the 3 cell types was rejected (p-value = 1.47 x 10-15).
This showed that at least one cell type, obviously ESC, had
a ST proportion significantly different than breast and
WBC.
Lowest SBS frequency in transcripts expressed in ESC
1,748; 583; and 860 RT out of the 1,959 that were
selected in the L-SAGE experiments were present in
100% of the 10 ESC, 100% of the 12 breast and 100% of
the 10 WBC experiments, respectively. For each experi-
ment, a global sbsRT proportion was calculated and the
means were determined, i.e. 0.14 (breast), 0.15 (WBC)
and 0.058 (ESC) (Figure 6b). ESC had thus the lowest
mean. We tested the significance of the differences be-
tween global sbsRT proportion means across the 3 cell
types. The hypothesis of normal distributions for the
transformed global proportions calculated on breast,
WBC and ESC were accepted with a Shapiro-Wilk test
(p-value = 0.30, 0.79 and 0.22 respectively). However, the
equality of variance was rejected by a Bartlett test (p-
value = 0.005). A non-parametric Kruskal-Wallis test
rejected the equality between the transformed global
sbsRT proportion means in breast, WBC and ESC with
a 5.4 x 10-5 p-value. This showed that ESC had a SBS
frequency in transcripts that was significantly different
from the other two cell types.
ST proportions and SBS frequencies correlate and
increase during cancer progression
In the previously mentioned series of 4 L-SAGE experi-
ments carried out on the biopsies of a single patient, 1healthy and 3 consecutive tumor stages, i.e. Low-Grade
Dysplasia (LGD), High-Grade Dysplasia (HGD) and
Adenocarcinoma (AC), were recorded [26]. The sums of
total tags counts for each 4 experiments were balanced
(mean = 75,735 tags, standard deviation = 2,061 tags). In
these 4 experiments, the ST proportions dramatically
increased from 0.38 (healthy) to ~0,52 (LGD, HGD) and
0.64 (AC) (Figure 7). Of particular note, the percent of
ST that could not be associated with any transcript also
increased from 83% in healthy to 87% in both LGD and
HGD, and 92% in AC. In the 4 experiments, 2,271 tags
were co-present and among them 1,435 belonged to the
list of the 1,959 L-SAGE RT. A global sbsRT proportion
was calculated for each experiment using the co-present
RT. Global sbsRT proportions increased from 0.33 in
healthy, to ~0.47 (LGD, HGD) and 0.66 in AC, showing
that SBS frequencies was increasing with the tumor
stage. Since SBS occurring in RT is a possible cause of
tag with transcript association failure, this may explain
why the percent of unassociated ST increased from
healthy to AC. No significant difference was observed
between LGD and HGD suggesting that these pheno-
types were not related to an increase of SBS in mRNA
sequences. The Pearson's coefficient calculated between
the ST and global sbsRT proportions on the 4 experi-
ments showed a strong correlation (0.98). ST proportion
seemed thus to be an accurate indicator of SBS fre-
quency in transcripts.
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In the present study, we provide evidence for an
increased frequency of SBS that occur in a population of
transcripts expressed in cancer cells. Known SNP, catalo-
gued cancer related somatic mutations and predicted or
validated targets of RNA-editing enzymes did not sup-
port the increased SBS frequency in cancer. However,
the transcripts but not the genome of healthy and
tumors cells were available and thus transcript and gen-
ome sequences both originating from the same patient
could not be directly compared. To fully confirm that
increased base conflicts exist between transcript and
genome sequences in patient’s tumors, back-to-back
exome sequencing and RNA-seq would be required.
Using Tag-seq, 1,123 RT had greater SBS in healthy than
in cancer cells, therefore questioning the reliability of
this result. In fact, ST had been removed from Tag-seq
experiments recorded in GEO and thus 30% of the tags
data was unavailable. As ST represent a reservoir of SBS,
their removal may have introduced a bias in sbsRT
accounting. Moreover, slight heterogeneity of sequencing
quality between platforms cannot be excluded. Some
Tag-seq experiments carried out in healthy cells may
have been produced with poor sequencing quality and
thus may have introduced more SBS than in cancer cells.
Finally sequence biases such as read redundancy have
been reported in deep sequencing. Using RNA-seq, read
redundancy can be cleaned by bioinformatics programs.
Conversely, tag redundancy produced by deep sequen-
cing bias cannot be cleaned in Tag-seq experiments. ST
have been considered as low quality sequences, i.e.
enriched in sequencing errors and may be excluded from
analysis by standard bioinformatics procedures. Here, we
agree with previous statements that in fact valuable in-
formation is available in ST [27]. Furthermore, L-SAGE
and Tag-seq may be so sensitive that they can detect
base errors introduced by the cell transcriptional ma-
chinery or RNA-editing. ST are thus an archive of
mRNA sequence alterations either due to sequencing
errors, TI, or RNA-editing and should not be sacrificed
for the benefit of disk space sparing. Moreover, the pro-
portion of ST per experiment has proved to be an accur-
ate indicator of SBS frequency in transcripts. An
unexpected high level of SBS in tags produced by
L-SAGE experiments had already been reported in a
previous study [28]. Using 29 publicly available L-SAGE
libraries - that were also used in our study - and aligning
the tags on the human genome sequence, the conclusion
that the sequencing error rate might have been underes-
timated was drawn since a large number of tags did not
match the genome after having taken into account the
currently accepted 1% base error rate of L-SAGE tags.
However, in this previous study both healthy and cancer
experiments were mixed, i.e. cancer was not suspectedto introduce additional SBS in transcripts. The molecu-
lar mechanism underlying increased TI in cancer is still
elusive. Brulliard et al. speculated that increased TI
might be due to defective transcription assisted proof-
reading activity. In fact, transcriptional fidelity relies i)
on the ability of RNA polymerases to select the correct
base before incorporation, ii) to impair RNA extension
beyond a mismatch, iii) to cleave a mismatched base at
the RNA 3’ boundary and resume RNA synthesis
[29,30]. Dysfunction at any of these 3 crucial steps is
likely to compromise RNA sequence integrity. However,
cancer related somatic mutations have not been reported
so far in genes coding for RNA polymerases. Conversely,
mice deficient for DNA polymerase δ proofreading activ-
ity have been associated with a high incidence of epithe-
lial cancer [31]. Mutations in genes that code for
proteins involved in mRNA synthesis could be searched
in patients showing an increased SBS frequency. In ESC,
the transcription of the genome is globally hyperactive
[32]. No information has been made available on tran-
scriptional fidelity in ESC. Comparing SBS frequencies
across different cell types, we uncovered that ESC had a
very low SBS frequency. This finding is in favor of a
transcriptional fidelity which might be greater in ESC
than in differentiated cells. We provided strong evi-
dences that SBS frequency is significantly increased for a
population of transcripts expressed in cancer cells. How-
ever, further investigations are required to determine
whether this feature is common to all cancers or
whether it is only present in some malignancies or in a
subset of patients.
Conclusions
SBS frequency in transcript sequences is heterogenously
distributed across cells, i.e. ESC have the lowest, cancer
cells have the greatest and healthy differentiated cells
may lie “in between”. Therefore, SBS frequency in tran-
script sequences could represent a new cancer specific
biomarker which may be useful to characterize patient’s
tumors. With the reduction of sequencing cost, cancer
diagnostic could be aided by the determination of SBS
frequency in transcripts expressed in tumors. In the fu-
ture, drugs or gene therapies which may prove particu-
larly efficient to treat patient’s tumors showing increased
SBS frequency in transcripts could be valuable and thus
intensively searched.
Additional files
Additional file 1: Generation of 17 distinct patterns for each RT.
Additional file 2: Risk that a sbsRT matches by chance the RT of a
transcript.
Additional file 3: L-SAGE and Tag-seq experiment sizes (sequencing
effort).
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healthy cells (Tag-seq).
Additional file 6: Manual checking of possible cancer related
somatic mutations altering RT with greater SBS frequencies in
cancer than in healthy cells (L-SAGE).
Additional file 7: Manual checking of possible cancer related
somatic mutations altering RT with greater SBS frequencies in
cancer than in healthy cells (Tag-seq).
Additional file 8: Manual checking of possible APOBEC1 RNA-
editing targets altering RT with greater SBS frequencies in cancer
than in healthy cells (L-SAGE).
Additional file 9: Manual checking of possible APOBEC1 RNA-
editing targets altering RT with greater SBS frequencies in cancer
than in healthy cells (Tag-seq).
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